Latest News
| 2013-03-18 | Biosign Corporate Update |
| 2013-03-15 | Biosign Corporate Update |
| 2013-03-05 | Biosign Announces Successful Heart Month Promotion |
| 2013-03-01 | Biosign Corporate Update |
| 2013-02-04 | Biosign Investor Update |
| 2013-01-16 | Biosign Technologies Announces Amended Closing On Private Placement |
| 2013-01-03 | Biosign Technologies Completes Private Placement |
| 2012-12-21 | Biosign Completes Non-Brokered Private Placement and Appoints EVP |
Telemedicine to hit $3 Billion in 2015
Biosign Technologies Inc currently markets our FDA-cleared Healthanywhere™ remote patient monitoring solutions to customers in both Canada and the United States, and we are aggressively pursuing new opportunities in both markets. A recent Frost & Sullivan survey estimates the American market for Home BP monitors at $939 Million, Automated BP meters at $300 Million and Health Stations at $36 Million, while iData estimates the US market for Telemedicine Services will reach $3.6 Billion by 2015. Biosign’s innovative Pulsewave™ Monitor is FDA-cleared and Health Canada licensed and is also marketed to customers in both Canada and the United States.
Product Roadmap
Built on a unique platform combining our proprietary Pulsewave™ cuff with algorithm-driven Cloud Diagnostics™ software, Biosign products are the world’s most flexible virtual medical instruments. Additional innovations in our research pipeline include:






